Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drug distributor Cardinal Health Inc raised its 2024 profit forecast on Tuesday, as it sees strong demand for specialty and generic medicines to continue to boost sales in its pharmaceuticals unit.

Cardinal Health raises 2024 profit forecast on drug distribution strength

Cardinal Health reported fiscal fourth-quarter earnings of $1.55 a share on revenue of $53.5 billion.

Cardinal Health Beats on Earnings, Raises Guidance on Strong Pharmaceutical Sales

Cardinal Health Inc.'s stock CAH slid 1% in premarket trade Tuesday, after the health services company swung to a loss for its fiscal fourth quarter from a profit a year ago. Dublin, Ohio-based Cardinal Health had a loss of $64 million, or 25 cents a share, for the quarter, after income of $138 million, or 50 cents a share, in the year-earlier period.

Cardinal Health's stock dips premarket after company swings to a loss

Fourth quarter revenue increased 13% to $53.5 billion Fourth quarter GAAP 1 operating earnings were $137 million and GAAP diluted loss per share was $0.25 Fourth quarter non-GAAP operating earnings increased 24% to $560 million and non-GAAP diluted EPS increased 48% to $1.55 Fourth quarter Pharmaceutical segment profit increased 12% to $504 million and Medical segment profit increased to $82 million Generated both operating cash flow and non-GAAP adjusted free cash flow of $2.8 billion and returned over $2.5 billion to shareholders in fiscal year 2023 2 Fiscal year 2024 non-GAAP EPS guidance raised to $6.50 to $6.75, from $6.45 to $6.70 DUBLIN, Ohio , Aug. 15, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2023 revenues of $53.5 billion, an increase of 13% from the fourth quarter of last year. GAAP operating earnings were $137 million, primarily due to a non-cash, pre-tax goodwill impairment charge of $368 million in the Medical segment, which reflects the financial update provided at Investor Day.

Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2023 at High End of Investor Day Guidance

American Tower

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

Fulton Financial

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Medtronic

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Philip Morris

TotalEnergies SE

Vanguard S&P 500 ETF

We received $941 in July dividend income. This was a 34.95% dividend increase compared to July 2022. One interesting benefit of moving the funds into VOO is that they pay dividends in an “off month” several times during the year. The Fulton July dividend has more than doubled since January and the Huntington dividend has grown over 50% in the same time period.

Bert's July 2023 Dividend Income Summary

Alcon Inc. - Registered Shares

Artivion

iRadimed

Penumbra

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Time to Buy These Medical Stocks as Earnings Approach

Align Technology

Eli Lilly

Health Care Select Sector SPDR Fund

After a couple of weeks where the broad market experienced some weakness, the healthcare sector is showing considerable resiliency. Over the last month, the Healthcare Select Sector ETF  XLV  has been the second strongest sector in the market, behind just the energy market.

Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength

Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Cardinal Health (CAH)

Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.

Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?

Automatic Data Processing

Albemarle

Lowe's

NextEra Energy

In recent years, dividend aristocrats have become a popular choice among investors of all stripes. Dividend aristocrats, or S&P 500 index components with at least 25 consecutive years of dividend growth, have historically delivered total returns on par with the S&P 500 but with lower volatility.

7 Dividend Aristocrats That Have Raised Their Payouts for 25 Years or More

Broadstone Net Lease

Bank of Nova Scotia

BRT Apartments

Chimera Investment

Eastman Chemical

Gap Inc

Coca-Cola

MDU Resources Group

Medical Properties Trust

NetApp

Oracle

J. M. Smucker

In July, we received a dividend income total of $1,421.13. The $200 dividend from Canada Imperial was reinvested and acquired almost 5 more shares, adding more income. July was probably one of the lowest number of stocks increasing their dividend for me.

Dividend Income Summary: Lanny's July 2023 Summary

Chubb

Johnson Controls

Kimberly-Clark

Mondelez

Altria

July was exciting as ever as my year-over-year numbers continue to highlight the trifecta magic of dividend investing, which includes adding fresh capital, dividend raises and basic compounding to create an ever increasing passive income stream. I have to say I'm quite pleased with my July totals. Not too far from that coveted four-digit milestone too. After all, dividends don't lie. It's real cash being returned to investors. With patience and consistency these results and better can be achieved.

Dividend Income Update July 2023

Health Care Services stocks have underperformed in the US market, but Cardinal Health has bucked the trend. CAH is one of the largest drug and medical product distributors, with strong earnings growth and a positive outlook. The firm is also buying back its shares with ample FCF. The stock is undervalued, with a compelling valuation and a powerful uptrend, making it a buy ahead of earnings on the 15th.

Cardinal Health: Better EPS Growth Clarity, Buying Back Shares, A Buy On Valuation

Airbnb

Lennar

MercadoLibre

AI and cloud play Oracle leads five stocks to watch near buy points, along with Amazon rival MercadoLibre.

AI Play Oracle, Amazon Rival Lead 5 Stocks Near Buy Points

National Vision Hlds

Henry Schein

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Top Estimates This Earnings Season

Johnson & Johnson

UnitedHealth Group

Everyone seems to be focused on the Nasdaq, as tech stocks lead the way higher. While that may be the case, we've seen soaring healthcare stocks too.

Buckle Up! 3 Healthcare Stocks Set to Soar to New Heights

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?

Apple

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

News for Cardinal Health Stock (CAH)